Physician
Endocrinology
Dr. Thomas C. Blevins, MD
|
|
Give Review
Thomas Blevins works in the field of Endocrinology. He went to Baylor College of Medicine. He has 6 awards "Meaningful Use Stage 1 Certification", "Diabetes Recognition Program", "Super Doctor", "Fellow (FACE)", "Diabetes Care Recognition" and "Top MD". Thomas Blevins has written publications. He has 15 publications published with PubMed. The lastest paper is: 'Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus.' Thomas Blevins is registered with Medicare.
Publications
- Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 Diabetes mellitus.
- Centralized Molecular Testing for Oncogenic Gene Mutations Complements the Local Cytopathologic Diagnosis of Thyroid Nodules.
- Glycemic Control after 6 Days of Insulin Pump Reservoir Use in Type 1 Diabetes: Results of Double-Blind and Open-Label Cross-Over Trials of Insulin Lispro and Insulin ...
- Anatabine supplementation decreases thyroglobulin antibodies in patients with chronic lymphocytic autoimmune (Hashimoto's) Thyroiditis: A randomized controlled clinica...
- Value and utility of self-monitoring of blood glucose in non-insulin-treated patients with type 2 Diabetes mellitus.
- Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover s...
- Professional continuous glucose monitoring in clinical practice 2010.
- Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 Diabetes.
- The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients With typ...
- Therapeutic options that provide glycemic control and weight loss for patients with type 2 Diabetes.
- Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 Diabetes.
- Control of postprandial glucose levels with insulin in type 2 Diabetes.
- DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 Diabetes.
- Statement by the American Association of Clinical Endocrinologists Consensus Panel on continuous glucose monitoring.
Schools
Baylor College Of Medicine
Baylor College Of Med
Procedures Preformed
- Continuous Glucose Monitoring
Conditions Treated
- Abnormal Thyroid
- Adrenal Insufficiency
- Adrenogenital Disorders
- Calcium Metabolism Disorders
- View All
Doctors Specialties
- Endocrinology
Accepted Insurances
Awards
- Meaningful Use Stage 1 Certification
- Diabetes Recognition Program
- Super Doctor
- Fellow (FACE)
- Diabetes Care Recognition
- Top MD
Education
-
Baylor College of Medicine
Hospital
-
Seton Medical Center Austin
Drug Facts
| NPI NUMBER | 1114992088 | |
| NPPES Provider LastName | BLEVINS | |
| NPPES Provider FirstName | THOMAS | |
| NPPES Provider ZIPCode | 78731 | |
| NPPES Provider State | TX | |
| Specialty Description | Endocrinology | |
| Total Claim Count | 8150.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1114992088 |
| Last Name Of The Provider | BLEVINS |
| First Name Of The Provider | THOMAS |
| View All |
Similar Doctors
|
|
Dr. Tira Chaicha-Brom, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Kavita Juneja, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Valerie D. Espinosa, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Luis Casaubon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pratima V. Kumar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maya B. Bledsoe, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Michael C. McClung, DC
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|